Results 211 to 220 of about 270,393 (395)

Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Fexuprazan, a potassium‐competitive acid blocker, is increasingly used for the treatment of gastroesophageal reflux disease in South Korea. While generally well tolerated, data regarding its hepatotoxic potential are scarce. We report a case of idiosyncratic drug‐induced liver injury in a 61‐year‐old woman following 2 months of fexuprazan therapy.
Sook Jin Seong   +5 more
wiley   +1 more source

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a
Anna Lundahl   +11 more
wiley   +1 more source

Eosinophilic fasciitis. [PDF]

open access: bronze, 1977
Samantha Stubbs, G. R. V. Hughes
openalex   +1 more source

Fusion Pores as Regulators of Quantal Size and Cellular Physiology

open access: yesBioEssays, EarlyView.
During regulated exocytosis, membrane fusion regulatory factors act directly on SNAREs and membrane lipids to control fusion pore dynamics. This, in turn, leads to a differential amount of cargo release (referred to in this article as “quantal size”) across various cell types, thereby triggering distinct physiological cues.
Bhavya R. Bhaskar   +3 more
wiley   +1 more source

Assessment of Small Airways Function in Eosinophilic Preserved Ratio Impaired Spirometry. [PDF]

open access: yesPulm Ther
Zhou T   +8 more
europepmc   +1 more source

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

open access: yesNew England Journal of Medicine, 2014
E. Bel   +7 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy